To recover your password please fill in your email address
Please fill in below form to create an account with us
Irinotecan Cetuximab Evaluation and the Cetuximab Response Evaluation Among Patients with G13D Mutation.
Randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS wild-type or G13D mutation
Patients with metastatic colorectal cancer with either KRAS WT or KRAS G13D mutation
Australian Lead Group:
Eva Segelov (Australia), Jeremy Shapiro (Australia)